NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

Authors

Andrea Wang-Gillam, Washington University School of Medicine in St. Louis
Richard A Hubner, The Christie NHS Foundation Trus
Jens T Siveke, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)
Daniel D Von Hoff, Translational Genomics Research Institute
Bruce Belanger, Ipsen Biopharmaceuticals, Inc.
Floris A de Jong, Servier
Beloo Mirakhur, Ipsen Biopharmaceuticals, Inc.
Li-Tzong Chen, National Health Research Institutes - National Institute of Cancer Research

Journal

European journal of cancer

Publication Date

2-1-2019

Volume

108

First Page

78

Last Page

87

Document Type

Open Access Publication

DOI

10.1016/j.ejca.2018.12.007

Rights and Permissions

Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019 Feb;108:78-87. doi.org/10.1016/j.ejca.2018.12.007. Copyright 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Wang-Gillam, Andrea; Hubner, Richard A; Siveke, Jens T; Von Hoff, Daniel D; Belanger, Bruce; de Jong, Floris A; Mirakhur, Beloo; and Chen, Li-Tzong, "NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors." European journal of cancer. 108, 78 - 87. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11782